Meiyi Su

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Shexiang Tongxin dropping pill for coronary microvascular disease: rationale and design of a multicenter randomized trial with a cardiopulmonary exercise testing primary endpoint and AI-enhanced myocardial contrast echocardiograph.

Shexiang Tongxin dropping pill for coronary microvascular disease: rationale and design of a multicenter randomized trial with a cardiopulmonary exercise testing primary endpoint and AI-enhanced myocardial contrast echocardiograph.

Journal: Frontiers in cardiovascular medicine

Published: May 08, 2026

Global burden and projections of cardiometabolic diseases attributable to high alcohol use: a comparative risk assessment based on the GBD 2021 study.

Global burden and projections of cardiometabolic diseases attributable to high alcohol use: a comparative risk assessment based on the GBD 2021 study.

Journal: Frontiers in nutrition

Published: September 04, 2025

Machine learning-based integration of pericoronary adipose tissue and clinical risk factors for cardiovascular risk prediction in type 2 diabetes: a retrospective cohort study.

Machine learning-based integration of pericoronary adipose tissue and clinical risk factors for cardiovascular risk prediction in type 2 diabetes: a retrospective cohort study.

Journal: European journal of medical research

Published: July 15, 2025

Efficacy and safety of Qishen granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

Efficacy and safety of Qishen granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

Journal: BMC complementary medicine and therapies

Published: April 05, 2025

Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway.

Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway.

Journal: Frontiers in pharmacology

Published: March 21, 2025

A necroptosis-related prognostic model for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma based on single-cell sequencing analysis and weighted co-expression network.

A necroptosis-related prognostic model for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma based on single-cell sequencing analysis and weighted co-expression network.

Journal: Frontiers in genetics

Published: July 01, 2022

Resveratrol and Angiogenin-2 Combined With PEGDA/TCS Hydrogel for the Targeted Therapy of Hypoxic Bone Defects via Activation of the Autophagy Pathway.

Resveratrol and Angiogenin-2 Combined With PEGDA/TCS Hydrogel for the Targeted Therapy of Hypoxic Bone Defects via Activation of the Autophagy Pathway.

Journal: Frontiers in pharmacology

Published: October 20, 2020

Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial.

Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial.

Journal: Trials

Published: February 25, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026